KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non ‐small cell lung cancer

Conclusion. This is the first comprehensive study to disclose that KAT2B is correlated with immune infiltrates and may serve as a novel biomarker predicting prognosis and response to immunotherapy in NSCLC.

Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research